Seminars in Hematology
Volume 37, Issue 3 , Pages 290-298 , July 2000

Management of patients with chronic, refractory idiopathic thrombocytopenic purpura

References 

  1. Abrahm J, Ellman L. Platelet transfusion in immune thrombocytopenic purpura. JAMA. 1976;236:1847–1847
  2. Aggarwal A, Doolittle G. Autoimmune thrombocytopenic purpura associated with hyperthyroidism in a single individual. South Med J. 1997;90:933–936
  3. Ahn YS, Harrington WJ, Mylvaganam R, et al.  Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med. 1984;100:192–196
  4. Ahn YS, Harrington WJ, Simon SR, et al.  Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308:1396–1399
  5. Ahn YS, Mylvaganam R, Garcia RO, et al.  Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med. 1987;107:177–181
  6. Akwari OE, Itani KMF, Coleman RE, et al.  Splenectomy for primary and recurrent immune thrombocytopenic purpura. Ann Surg. 1987;206:529–541
  7. Almagro D. Danazol in idiopathic thrombocytopenic purpura. Acta Haematol. 1985;74:120
  8. Ambriz R, Pizzuto J, Morales M, et al.  Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouv Rev Fr Hematol. 1986;28:275–279
  9. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330:1560–1564
  10. Arrowsmith JB, Dreis M. Thrombocytopenia after treatment with danazol. N Engl J Med. 1986;314:585–585
  11. Aspnes GT, Pearson HA, Spencer RP, et al.  Recurrent idiopathic thrombocytopenia purpura with “accessory” splenic tissue. Pediatrics. 1975;55:131–134
  12. Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989;149:1959–1961
  13. Baumann MA, Menitove JE, Aster RH, et al.  Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104:808–809
  14. Blanchette VS, Hogan VA, McCombie NE, et al.  Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion. 1984;24:388–394
  15. Bolton-Maggs PHB, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350:620–623
  16. Brodsky R, Petri M, Smith BD, et al.  Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998;129:1031–1035
  17. Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol. 1988;70:341–344
  18. Bussel JB, Saal S, Gordon B. Combined plasma exchange and intravenous gammaglobulin in the treatment of patients with refractory immune thrombocytopenic purpura. Transfusion. 1988;28:38–41
  19. Cahill MR, Macey MG, Cavenagh JD, et al.  Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol. 1998;100:358–364
  20. Carbone PP, Bono V, Frei E, et al.  Clinical studies with vincristine. Blood. 1963;21:640–646
  21. Carr JM, Kruskall MS, Kaye JA, et al.  Efficacy of platelet transfusions in immune thrombocytopenia. Amer J Med. 1986;80:1051–1054
  22. Caulier MT, Rose C, Roussel MT, et al.  Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: A report on 10 cases. Br J Haematol. 1995;91:477–479
  23. Cavanna L, Vallisa D, Berte R, et al.  Severe immune thrombocytopenic purpura relapse after alpha-interferon in chronic myeloid leukemia, successfully treated with cyclosporine. Am J Hematol. 1994;47:255–256
  24. Centers for Disease Control and Prevention . Recommendations of the Advisory Committee on Immunization Practices: Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR. 1993;42:1–18
  25. Cordiano I, Betterle C, Spadaccino CA, et al.  Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): Overlapping syndromes?. Clin Exp Immunol. 1998;113:373–378
  26. Cortelazzo S, Finazzi G, Buelli M, et al.  High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77:31–33
  27. Demiroglu H, Dündar S. High-dose pulsed dexamethasone for immune thrombocytopenia. N Engl J Med. 1997;337:425–426
  28. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. In: Semin Oncol. 16:1989;p. 337–346
  29. Dubbeld P, Hillen HFP, Schouten HC. Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP). Eur J Haematol. 1994;52:233–235
  30. Eraklis AJ, Fillwe RM. Splenectomy in childhood: A review of 1413 cases. J Pediatr Surg. 1972;7:382–388
  31. Facon T, Caulier MT, Fenaux P, et al.  Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol. 1992;41:184–189
  32. Facon T, Caulier MT, Wattel E, et al.  A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: A report on 42 patients. Br J Haematol. 1994;86:678–680
  33. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet. 1972;1:568–569
  34. Fenaux P, Quiquandon I, Caulier MT, et al.  Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: A report on 43 cases. Blut. 1990;60:238–241
  35. Figueroa M, Gehlsen J, Hammond D, et al.  Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328:1226–1229
  36. Figueroa M, McMillan R. 2-Chlorodeoxyadenosine in the treatment of chronic refractory immune thrombocytopenic purpura. Blood. 1993;81:3484–3485
  37. Fraser IS, Burridge J. Danazol treatment and platelet function. Med J Aust. 1980;1:313–314
  38. Frederiksen H, Schmidt K. The incidence of ITP in adults increases with age. Blood. 1999;94:909–913
  39. Fujimura K, Takafuta T, Kuriya S, et al.  Recombinant human interferon α-2b (rh IFNα-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP). Am J Hematol. 1996;51:37–44
  40. Gardner FH, Helmer RE. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA. 1980;243:35–37
  41. George JN, El-harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In:  Beutler E,  Lichtman MA,  Coller BS, et al. editor. Williams Hematology. New York, NY: McGraw-Hill; 1995;p. 1315–1355
  42. George JN, Raskob GE, Bussel J, et al.  Safety and effect on platelet count of repeated doses of monoclonal antibody to CD40 ligand in patients with chronic ITP. Blood. 1999;94:19a; (suppl 1, abstr)
  43. George JN, Rizvi MA. Management issues in idiopathic thrombocytopenic purpura. In:  Alving BM, et al. editor. Blood Components and Pharmacologic Agents in the Treatment of Congenital and Acquired Bleeding Disorders. Bethesda, MD: American Association of Blood Banks; 2000;p. 263–288
  44. George JN, Woolf SH, Raskob GE, et al.  Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40
  45. Godeau B, Durand JM, Roudot-Thoraval F, et al.  Dapsone for chronic autoimmune thrombocytopenic purpura: A report of 66 cases. Br J Haematol. 1997;97:336–339
  46. Guthrie TH, Brannan DP, Prisant LM. Idiopathic mrombocytopenic purpura in the older adult patient. Am J Med Sci. 1988;296:17–21
  47. Hwang YF, Hamilton HE, Sheets RF. Vinblastine-induced thrombocytosis. Lancet. 1969;2:1075–1076
  48. Johnson WW, Meadows DC. Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N Engl J Med. 1971;284:290–294
  49. Kabisch A, Kroll H, Wedi B, et al.  Severe adverse effects of protein A immunoadsorption. Lancet. 1994;343:116
  50. Krause JR. Chronic idiopathic thrombocytopenic purpura (ITP): Development of acute nonlymphocytic leukemia subsequent to treatment with cyclophosphamide. Med Pediatr Oncol. 1982;10:61–65
  51. Kurata Y, Miyagawa S, Kosugi S, et al.  High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost. 1994;71:184–187
  52. Kyle RA, Gertz MA. Second malignancies after chemotherapy. In:  Perry MC editors. The Chemotherapy Sourcebook. Baltimore, MD: Williams & Wilkins; 1992;p. 689–702
  53. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. In: Semin Thromb Hemost. 3:1977;p. 160–174
  54. Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol. 1999;105:871–875
  55. Lim SH, Kell J, Al-Sabah A, et al.  Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura. Lancet. 1997;349:475–475
  56. Lipp E, Von Feiten A, Sax H, et al.  Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998;60:283–288
  57. Lortan JE. Management of asplenic patients. Br J Haematol. 1993;84:566–569
  58. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med. 1990;112:352–364
  59. Marino C, Cook P. Danazol for lupus thrombocytopenia. Arch Intern Med. 1985;145:2251–2252
  60. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307–314
  61. McVerry BA, Auger M, Bellingham AJ. The use of danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol. 1985;61:145–148
  62. Nakamura R, Huhn RD, Read EJ, et al.  Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia (AITP): Interim report. Blood. 1999;94(suppl 1):646a; abstr
  63. Nojima J, Suehisa E, Kuratsune H, et al.  High prevalence of thrombocytopenia in SLE patients with a high level of anticardiolipin antibodies combined with lupus anticoagulant. Am J Hematol. 1998;58:55–60
  64. Peng J, Friese P, Heilmann E, et al.  Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood. 1994;83:161–166
  65. Perotta A, Sunneberg TA, Scott J, et al.  Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Blood. 1999;94(suppl 1):14a; abstr
  66. Pignon J-M, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol. 1993;83:343–345
  67. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood. 1984;64:1179–1183
  68. Quiquandon I, Fenaux P, Caulier MT, et al.  Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura; a report on 53 cases. Br J Haematol. 1990;74:223–228
  69. Rabinowe SN, Miller KB. Danazol-induced thrombocytopenia. Br J Haematol. 1987;65:383–384
  70. Rebulla P, Finazzi G, Marangoni F, et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870–1875
  71. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol. 1997;137:209–217
  72. Reid MM. Chronic idiopathic thrombocytopenic purpura: Incidence, treatment, and outcome. Arch Dis Child. 1995;72:125–128
  73. Robertson JH, Crozier EH, Woodend BE. The effect of vincristine on the platelet count in rats. Br J Haematol. 1970;19:331–337
  74. Rovo A, Penchasky D, Korin J, et al.  Splenectomy in idiopathic thrombocytopenic purpura (ITP). Effective, yes, but for how long. Blood. 1999;92(suppl 1):177a; abstr
  75. Scaradavou A, Woo B, Woloski BMR, et al.  Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood. 1997;89:2689–2700
  76. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med. 1995;122:187–188
  77. Shirota T, Yamamoto H, Fujimoto H, et al.  Cyclic thrombocytopenia in a patient treated with cyclosporine for refractory idiopathic thrombocytopenic purpura. Am J Hematol. 1997;56:272–276
  78. Skoda RC, Tichelli A, Tyndall A, et al.  Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol. 1997;99:56–57
  79. Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol. 1978;7:523–539
  80. Smith AG, Prentice AG, Lucie NP, et al.  Acute myelogenous leukaemia following cytotoxic therapy: Five cases and a review. Q J Med. 1982;51:227–240
  81. Snyder HW, Cochran SK, Balint JP, et al.  Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood. 1992;79:2237–2245
  82. Stasi R, Stipa E, Masi M, et al.  Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436–442
  83. Stasi R, Stipa E, Masi M, et al.  Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203–4208
  84. Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med. 1984;144:2198–2200
  85. Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamide. Am J Hematol. 1976;1:97–104
  86. Wandt H, Frank M, Ehninger G, et al.  Safety and cost effectiveness of a 10 X 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–3606
  87. Warne GL, Fairley KF, Hobbs JB, et al.  Cyclophosphamideinduced ovarian failure. N Engl J Med. 1973;289:1159–1162
  88. Woolf SH. Shared decision-making: The case for letting patients decide which choice is best. J Fam Prac. 1997;45:205–208

PII: S0037-1963(00)90107-0

Seminars in Hematology
Volume 37, Issue 3 , Pages 290-298 , July 2000

Article Tools